By elucidating the commonly used terms in RCM for non-melanocytic skin tumors and the RCM characteristics of common diseases along with their corresponding histopathological manifestations, we aim to enhance the understanding of the correlation between RCM and histopathology. This will in turn improve diagnostic and therapeutic proficiency, and promote further standardization and application of RCM in the field of non-melanocytic skin tumors. Additionally, filling the gap in our country's guidelines or expert consensus on RCM application in the field of non-melanocytic skin tumors will contribute to the standardization and broader utilization of RCM in clinical practice.

Lung cancer is the leading cause of the incidence and mortality of malignant tumors in China. The 5-year survival rate released in 2018 for China (2012-2015) was 19.7%, which is lower than the 5-year survival rates of Japan (33%) and South Korea (25%) in Asian countries from 2010 to 2014. Early diagnosis can significantly improve the 5-year overall survival rate and prognosis of lung cancer patients. But about 75% of patients in our country are diagnosed with advanced lung cancer missed the best opportunity for curative surgery. The early diagnosis and treatment of lung cancer are key to improving the prognosis of the disease. Therefore, experts from the Academic group of lung cancer in Chinese Thoracic Society and Chinese Alliance Against Lung Cancer Expert Group formulated the "Chinese Expert Consensus on the Diagnosis and Treatment of Lung Nodules" in 2015 to standardize the diagnosis and treatment of lung nodules. In 2018, this consensus was updated to formulate the "Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2018 edition)" , and widely applied in multiple Branch Centre of Chinese Alliance Against Lung Cancer, proposing the "Intelligent Treatment of Million Early Lung Cancer Project". On the basis of applied experience of the expert consensus in recent years, with reference to the latest evidence has been updated, “Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2023 version) ” was formulated. The updated content of this consensus mainly includes the following aspects: 1) defining the screening age of high-risk lung cancer populations in China based on the national conditions, and updating relevant lung cancer epidemiological data; 2) Propose definition of “difficult-to-determine pulmonary nodules” to avoid delaying the diagnosis and treatment; 3) Scientific evaluation of pulmonary nodules assisted by AI and proposing human-machine MDT to avoid the limitations of AI; 4) The evaluation of pulmonary nodules was divided into routine and individualized evaluations for different populations, and recommendations were made based on evidence-based management guidelines for different types and sizes of pulmonary nodules. In the updated Consensus, 27 consensus points were recommended to provide reference for clinicians in order to improve the prognosis of lung cancer in China.

Diabetes and prediabetes in breast cancer patients are widespread and seriously affects the quality of life and prognosis of breast cancer patients. As the overall survival of early breast cancer women continues to increase, blood glucose abnormality is getting attention gradually. However, there is still a lack of targeted guidelines or consensus for the management of diabetes and prediabetes in breast cancer patients. Based on the guideline and the clinical experience of multiple clinical centers, the Society of Clinical Cancer Research Administration of China Anti-Cancer Association, Breast Cancer Rehabilitation Committee of China Anti-Cancer Association, Chongqing Federation of Clinical Medical Research, and the Society of Onco-endocrinology of Chongqing Anti-Cancer Association thoroughly discussed and formulated the Chinese Expert Consensus on Management of Diabetes and Prediabetes in Female Breast Cancer Patients, in order to further standardize the management of patient’s blood glucose abnormality to improve the patient’s life quality and prognosis.

The aim is to improve the accuracy and consistency of RCM image interpretation, increase the early detection rate of cutaneous melanocytic tumors, reduce the risk of misdiagnosis and missed diagnosis, and promote reliable and standardized application of RCM in the diagnosis and treatment of cutaneous melanocytic tumors.

While the effectiveness and safety of PCI are widely recognized, issues such as no-reflow and slow-flow phenomenon, ischemia-reperfusion injury, perioperative myocardial damage, in-stent restenosis, and in-stent thrombosis persist, which may impact the long-term survival quality and treatment outcomes of patients. Therefore, seeking additional therapeutic measures is of paramount importance to improve the treatment efficacy of PCI and the quality of life of patients. In recent years, high-quality evidence from evidence-based medicine has demonstrated the advantages of traditional Chinese medicine (TCM) in the treatment of myocardial infarction (MI). This continuous stream of evidence-based medicine provides a solid foundation for the formulation of guidelines. Given the increasingly urgent demand for TCM in the perioperative period of MI PCI and the complementary advantages of TCM and Western medicine in different treatment stages, it is imperative to develop dynamic clinical practice guidelines for the perioperative period of MI PCI with traditional Chinese medicine for promoting blood circulation and removing blood stasis.